Efficacy of recombinant human interferon combined with human immunoglobulin in treating infants with severe respiratory syncytial virus pneumonia
DONG Huiru
FENG Lei
SHI Shufeng
FU Hui
Abstract：Objective To explore the efficacy of recombinant human interferon α-1b(rhIFNα-1b nebulization)com-bined with human immunoglobulin in the treatment of infants aged 0-3 months with severe respiratory syncytial virus pneumo-nia.Methods A total of 78 infants aged 0-3 months with respiratory syncytial virus pneumonia admitted to Children's Hospital Affiliated of Zhengzhou University from February 2022 to December 2024 were retrospectively analyzed and divided into 3 groups according to the treatment methods:the interferon group(26 cases,treated with rhIFNα-1b nebulization),the immuno-globulin group(29 cases,treated with human immunoglobulin),and the combination group(23 cases,treated with rhIFNα-1b nebulization combined with human immunoglobulin).All the three groups were given routine symptomatic and supportive treat-ment.The clinical efficacy,time of symptom relief,and the incidence of adverse reactions were analyzed and compared among the three groups.Results The total effective rate of the combination group was 95.65%(22/23),higher than that of the interfer-on group(69.23%,18/26)(χ2=4.057,P<0.05)and the immunoglobulin group(65.52%,19/29)(χ2=6.984,P<0.05).The recovery times of pulmonary rales and body temperature,as well as the relief times of respiratory distress and cough in the combination group were(3.85±0.51)days,(1.95±0.60)days,(2.63±0.58)days,and(4.72±1.13)days,respectively,all shorter than those in the interferon group((4.62±0.42)days,(2.40±0.70)days,(3.12±0.97)days,and(5.49±1.25)days,respectively)(t=5.783,2.400,2.110,2.250,all P<0.05)and the immunoglobulin group((4.75±0.38)days,(2.47±0.74)days,(3.22±0.94)days,and(5.58±1.30)days,respectively)(t=7.294,2.731,2.636,2.508,all P<0.05).One case of laryngeal edema occurred in the interferon group,one case of rash occurred in the immunoglobulin group,and no obvious adverse reactions were observed in the combina-tion group.There was no statistically significant difference in the incidence of adverse reactions among the three groups(χ2=0.867,P>0.05).Conclusion The combination of rhIFNα-1b nebulization and human immunoglobulin in the treatment of infants aged 0-3 months with severe respiratory syncytial virus pneumonia is remarkable,effectively alleviating clinical symptoms with high safety.
Keywords：recombinant human interferon α-1bhuman immunoglobulin0-3 months oldrespiratory syncytial viruspneumonia
Publication Date：2025-10-25
Online Publishing Date：2025-11-03(First online date of this platform, not the publication date of the document)
Pages：5( 1273-1277 )